Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 7,500 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 7,500 shares of Enliven Therapeutics stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $20.03, for a total transaction of $150,225.00. Following the completion of the sale, the insider now owns 977,688 shares of the company's stock, valued at approximately $19,583,090.64. This trade represents a 0.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN traded down $0.16 during trading on Friday, reaching $21.21. The stock had a trading volume of 420,759 shares, compared to its average volume of 293,470. The stock has a market cap of $1.04 billion, a PE ratio of -11.12 and a beta of 1.07. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03. The firm's 50 day moving average price is $18.05 and its two-hundred day moving average price is $20.85.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). On average, research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its stake in Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after acquiring an additional 1,114 shares during the period. GAMMA Investing LLC grew its holdings in shares of Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after purchasing an additional 2,630 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Enliven Therapeutics during the 1st quarter worth approximately $60,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Enliven Therapeutics during the 4th quarter worth approximately $97,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Enliven Therapeutics in the 4th quarter worth approximately $112,000. 95.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on ELVN shares. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. Jones Trading reduced their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $37.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.